-Conference Call Scheduled for Thursday, November 1, 2018 at 4:30pm
ET-
NEWARK, Calif.--(BUSINESS WIRE)--Oct. 18, 2018--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced that the Company will release second quarter
2018 financial results on Thursday, November 1, 2018 after the close of
market. Revance will host a corresponding conference call and a live
webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results
and provide a business and pipeline update.
Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers and reference conference ID: 2377607; or from the
webcast link in the investor relations section of the company's website
at: www.revance.com.
A replay of the call will be available beginning November 1,
2018 at 4:30pm PT/7:30pm ET to November 2, 2018 at 4:30pm PT/7:30pm ET.
To access the replay, dial (855) 859-2056 or (404) 537-3406 and
reference conference ID: 2377607. The webcast will be available in the
investor relations section on the company's website for 30 days
following the completion of the call.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology leader
developing neuromodulators for the treatment of aesthetic and
therapeutic conditions. Revance uses a unique proprietary, stabilizing
excipient peptide technology to create novel, differentiated therapies.
The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002),
is in clinical development for a broad range of aesthetic and
therapeutic indications, including glabellar lines, cervical dystonia,
plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has
the potential to be the first long-acting neuromodulator. The company is
advancing a robust pipeline of injectable and topical formulations of
daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005007/en/
Source: Revance Therapeutics, Inc.
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert,
714-325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com